Home › Trial NCT06825208
Etoposide Plus Benmelstobart Followed by Maintenance Therapy of Benmelstobart Plus Anlotinib in First-line Treatment of Elderly Patients with Extensive Stage Small Cell Lung Cancer: a Single-arm, Prospective Trial
- Trial IDNCT06825208
- StatusNot Yet Recruiting
- PhaseN/A
- Study typeObservational
- SponsorNanjing First Hospital, Nanjing Medical University
- Enrollment29
- Start date2025-02
- ConditionsSmall Cell Lung Cancer Extensive Stage · ELDERLY PEOPLE
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.